Nigerian Judge Orders Arrests Of 3 Pfizer Heads

This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.

The New York Sun

KANO, Nigeria — A judge in Nigeria has ordered the arrest of three top officials of the American-based drug company Pfizer Inc., saying they failed to honor an order to appear in court over a $2 billion suit the company is facing for a 1996 drug trial, court papers showed.

Judge Shehu Atiku, sitting in the northern city of Kano on Monday, said his ruling November 6 that the officials of the Pfizer subsidiary in Nigeria should appear in court were not heeded at that resumed sitting.

The officials to be arrested include the head of Pfizer in Nigeria, Ngozi Edozien, and senior officials Lare Baale and Segun Donguro, the court papers said.

The now-controversial trials for the antibiotic Trovan were conducted in Kano on 200 children during a meningitis epidemic in 1996. Nigeria alleges Pfizer conducted the trials illegally, without the full knowledge and consent of the government and the parents, causing the death of 11 children and injury to dozens of others.

The company, headquartered in New London and Groton, Conn., has always denied any wrongdoing and insists the drug saved lives. A message left with Pfizer headquarters in New York was not immediately returned yesterday.

Nigeria’s Kano state and the federal government have instituted separate civil and criminal cases against Pfizer. The federal authorities demand $7 billion in damages.


The New York Sun

© 2025 The New York Sun Company, LLC. All rights reserved.

Use of this site constitutes acceptance of our Terms of Use and Privacy Policy. The material on this site is protected by copyright law and may not be reproduced, distributed, transmitted, cached or otherwise used.

The New York Sun

Sign in or  create a free account

or
By continuing you agree to our Privacy Policy and Terms of Use